Tryptophan pathway regulated by the rate-limiting enzyme, indoleamine-2,3-dioxygenase (IDO-1), has evolved as a therapeutic target in immunosuppression-induced cancer autoinflammatory diseases [53,54,55,56]. Here, IDO2 is linked to cancer.